SOST and chronic kidney disease: Thus, although sclerostin has potential to be a marker of risk stratification in KTR, more studies including movement to surrogate to clinical outcomes are needed to determine if sclerostin has can be used as a clinically actionable marker of BM-CKD in KTRs.